Applied BioSciences Launches New E-Commerce Experience
LOS ANGELES (PRWEB) JULY 19, 2018
Applied BioSciences Corp. (OTCQB: APPB), a diversified cannabinoid therapeutics company focused on the medical, bioceutical and pet health industries, today announced that the Company has launched a new ecommerce experience for Remedi, a collaboration of hemp and CBD industry professionals.
The new and improved e-commerce experience, located at remedishop.com, offers the well-known brand of hemp-derived cannabidiol (CBD) isolate-infused gummies, topical creams, and tinctures. The widely reported benefits of activated hemp extract include anti-inflammatory, neuro-regenerative, stress regulator and more.
Across the most popular Remedi product lines are organic CBD gummies, in both day and night formulas, and all-natural topical CBD lotions for pain and inflammation. The testimonials featured on the site are all 100% real customer stories.
The Company continues to see increasing sales and visibility through its comprehensive suite of hemp-derived product offerings, including Remedi, RemediPlus, TherPet and patented CanaGel™ hemp oil gel melts. The wide-ranging product line uses industrial hemp as an input to produce high-quality CBD for a variety of health and wellness solutions.
“Remedi continues to be at the forefront of the cannabinoid market, first using organically grown plants, without pesticides or herbicides as our main ingredient and now quickly and easily providing consumers with a variety of tinctures, topical creams and alternatives to the growing demand of this space. As Applied BioSciences continues to launch our product lines in select specialty and retail stores, people will also be able to visit remedishop.com to find holistic health and wellness alternatives that best suit their lifestyle,” stated Chris Bridges, president of Applied BioSciences Corp.
Applied BioSciences uses organic ingredients and formulations that were created to target common ailments in the health and wellness industry. The products use industrial hemp as an input to produce high-quality CBD for a variety of health and wellness solutions. The Company’s innovative formulation utilizes the full-spectrum cannabis plant mixed with hemp seed oil.
Applied BioSciences products are USDA-NOP certified organic, non-GMO, vegan, paleo, gluten-free, sugar-free and THC-free. Not all hemp is created equal. Our CBD oil is made from non-GMO, pesticide-free, CO2-extracted hemp oil. The products are formulated with organic 99%+ pure cannabidiol along with our proprietary blend of certified organic botanicals, herbals and essential oils to further optimize bioavailability.
About Applied BioSciences Corp.
Applied BioSciences Corp. (http://www.appliedbiocorp.com) is a diversified company focused on multiple areas of the medical, bioceutical and pet health industry. As a leading company in the CBD and Pet health space, the company is currently shipping to the majority of the states as well as to 5 international countries. The company is focused on selected investment, consumer brands, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media fields.
The company has several strategic partnerships and investments currently in place and is actively pursuing additional partnerships and strategic growth opportunities.
Based in Colorado, Remedi is a collaboration project of hemp and CBD industry professionals. With an advisory board of scientists, physicians, farmers, and extraction specialists, Remedi’s hemp CBD-infused products focus on delivery methods with proven and noticeable effects. Learn more at: https://www.remedishop.com/
Email: firstname.lastname@example.org or email@example.com
To be added to the Applied BioSciences email distribution list, please email firstname.lastname@example.org with “APPB” in the subject line.
Official Website: http://www.appliedbiocorp.com
Facebook @remedicbd & @therpetcbd
Instagram @remedishop & @therpet
Twitter @remedishop & @therpet
Safe Harbor Statement
Except for historical information contained herein, statements in this release may be forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Applied Biosciences Corp. (the “Company”) or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company’s filings with the Securities and Exchange Commission. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as (i) the development and protection of our brands and other intellectual property, (ii) the need to raise capital to meet business requirements, (iii) significant fluctuations in marketing expenses, (iv) the ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of our products and services, (v) the Company’s ability to conduct the business if there are changes in laws, regulations, or government policies related to cannabis, (vi) management’s ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and (vii) other information that may be detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE: Applied BioSciences Corp.
Released July 19, 2018